Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Merkel Cell Carcinoma
Drug:
Opdivo (nivolumab)
(
PD1 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
10/02/2019
Excerpt:
NCCN Recommendations for Selection of Systemic Therapy for Distant Metastatic Disease…3 checkpoint immunotherapies (avelumab, pembrolizumab, and nivolumab) recommended by NCCN as options for metastatic MCC…
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.